A2A

A2A Pharmaceuticals leverages proprietary computational systems, including A.I., to accelerate development of novel drug alternatives. Focus areas include unmet needs in oncology, drug-resistant bacterial infections, and other life-threatening diseases. A2A is a clinical-stage oncology company whose lead asset AO-252 is a first-in-class PPI inhibitor of TACC3 in Phase 1 dose escalation for ovarian, triple-negative breast, and endometrial cancer patients. The company has reported tumor reduction in a majority of patients in its 4b BID cohort at 160mg, with no dose-limiting toxicity observed thus far.